Making sense of HDAC2 mutations in colon cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

1. Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy.Signal transduction and targeted therapy · 2024
   Review
2. Targeting HDAC2-Mediated Immune Regulation to Overcome Therapeutic Resistance in Mutant Colorectal Cancer.Cancers · 2023
   Article
3. Targeting Histone Deacetylases in Diseases: Where Are We?Antioxidants & redox signaling · 2015
   Review
4. Histones: Controlling Tumor Signaling Circuitry.Journal of carcinogenesis & mutagenesis · 2013
   Article
5. Regulating the regulators: the post-translational code of class I HDAC1 and HDAC2.Journal of biomedicine & biotechnology · 2011
   Review

Corrections and comments

• Comment on
  An inactivating mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1.2008

Authors and funding

1 author at 1 institution in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as